Royalty Pharma plc (RPRX) — QMA analysis
Sector: Healthcare · Market cap: $19.2B · Price: $63.86 · Data as of 2026-10-23
Royalty Pharma plc has an above-average composite score of 64/100, higher score than 96% of 22,734 tracked stocks. The highest-scoring layer is Catalysts; the lowest is Insider activity.
What 12 data layers say about RPRX
The composite fuses insiders, congressional trades, institutional 13F positions, fundamentals, momentum, seasonality and more into a single number.
| Layer | Score |
|---|---|
| Fundamental value (FVS) | 69/100 |
| Earnings quality (EQS) | 60/100 |
| Technical trend (TSS) | 43/100 |
| Relative strength (RS) | 74/100 |
| Momentum (USS) | 56/100 |
| Insider activity (IAS) | 14/100 |
| Off-exchange trading (FINRA) / large flows (WHS) | 69/100 |
| Institutional 13F (IFS) | 65/100 |
| Options flow (OFS) | 64/100 |
| News sentiment (NSS) | 49/100 |
| Analysts / transcripts (ATS) | 58/100 |
| Catalysts (XS) | 88/100 |
What does the QMA model currently show for Royalty Pharma plc?
The composite score is an entry point, not a signal. What matters is layer confluence — whether they point the same direction.
For RPRX the layers diverge — some score high (Catalysts), others low (Insider activity). The divergence is itself information: the model does not give a clear-cut picture. The score is an input into your own research, not a recommendation.
RPRX insider & smart money activity
Over the recent period we record 1 reported insider purchases and 10 sales for RPRX: predominance of reported sales (by dollar value). A description of the data layer, not an instruction.
RPRX seasonality
RPRX is currently in its seasonal window October 1–28 with a hit rate of 71% and an average move of 0.7% (7 years of history).
Historical data does not guarantee future results.
RPRX dividend
Royalty Pharma plc currently carries a dividend yield of 1.45% and has paid for 7 years in a row.
How RPRX compares
Similar stocks from the same sector:
Frequently asked questions
What is the composite score for RPRX stock?
64/100 (grade B) as of 2026-10-23, fusing 12 data layers. An analytical score, not advice.
Are insiders buying RPRX stock?
Over the recent period, reported: purchases 1, sales 10 (purchases $37.5K, sales $13M). Insider activity: predominance of reported sales (by dollar value) — a description of reported data, not a trade instruction.
Where can I see live RPRX data?
Live RPRX data and the full screener are part of full access. Registration is free with no card — trial full access, then the free plan with a delayed data sample.
Explore more — for free
The RPRX score is just the start. Keep going free in the QMA magazine — analysis, tools and learning with no payment up front.
Want the full RPRX analysis with all layers and live data? Open RPRX detail →
Data from SEC and public markets. QMA is an analytical tool, not a registered investment advisor. No content on this page is investment advice or an instruction to buy or sell. Past performance does not guarantee future results.
⚠️ Important Notice: QMA is an analytical and educational tool, not investment advice. Scores, detections and ratings are descriptive, not buy/sell instructions. QMA is not a registered investment advisor (SEC / FINRA / MiFID II / ČNB). Consult a licensed financial advisor before any investment. Past performance does not guarantee future results; all investments carry the risk of capital loss.
Operator: Jaroslav Vojtášek · IČO: 48783447 · Place of business: U Jízdárny 577, 747 64 Velká Polom, Czech Republic · Register: Sole trader registered in the Czech Trade Licensing Register · E-mail: [email protected]